A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trial
| Autor: | Hortobagyi, G.N. 1, ∗, Lacko, A. 2, Sohn, J. 3, Cruz, F. 4, Ruiz Borrego, M. 5, Manikhas, A. 6, Hee Park, Y. 7, Stroyakovskiy, D. 8, Yardley, D.A. 9, Huang, C.-S. 10, Fasching, P.A. 11, Crown, J. 12, Bardia, A. 13, Chia, S. 14, Im, S.-A. 15, Martin, M. 16, Loi, S. 17, Xu, B. 18, Hurvitz, S. 19, Barrios, C. 20, Untch, M. 21, Moroose, R. 22, Visco, F. 23, Parnizari, F. 24, Zarate, J.P. 25, Li, Z. 25, Waters, S. 26, Chakravartty, A. 25, Slamon, D. 13 |
|---|---|
| Zdroj: | In Annals of Oncology |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|